CA2730804A1 - Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses - Google Patents

Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses Download PDF

Info

Publication number
CA2730804A1
CA2730804A1 CA2730804A CA2730804A CA2730804A1 CA 2730804 A1 CA2730804 A1 CA 2730804A1 CA 2730804 A CA2730804 A CA 2730804A CA 2730804 A CA2730804 A CA 2730804A CA 2730804 A1 CA2730804 A1 CA 2730804A1
Authority
CA
Canada
Prior art keywords
amino acid
acid residue
sequence
amyloid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2730804A
Other languages
English (en)
French (fr)
Inventor
Stefan Barghorn
Heinz Hillen
Rohinton Edalji
Leo Barrett
Paul Richardson
Liping Yu
Edward Olejniczak
John Harlan
Thomas Holzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Original Assignee
Abbott GmbH and Co KG
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG, Abbott Laboratories filed Critical Abbott GmbH and Co KG
Publication of CA2730804A1 publication Critical patent/CA2730804A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2730804A 2008-07-25 2009-07-24 Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses Abandoned CA2730804A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8358908P 2008-07-25 2008-07-25
US61/083,589 2008-07-25
PCT/US2009/051721 WO2010011947A2 (en) 2008-07-25 2009-07-24 AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES

Publications (1)

Publication Number Publication Date
CA2730804A1 true CA2730804A1 (en) 2010-01-28

Family

ID=41570887

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2730804A Abandoned CA2730804A1 (en) 2008-07-25 2009-07-24 Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses

Country Status (7)

Country Link
US (1) US20110092445A1 (cg-RX-API-DMAC10.html)
EP (1) EP2303920A4 (cg-RX-API-DMAC10.html)
JP (1) JP2011529084A (cg-RX-API-DMAC10.html)
CN (1) CN102203124A (cg-RX-API-DMAC10.html)
CA (1) CA2730804A1 (cg-RX-API-DMAC10.html)
MX (1) MX2011000975A (cg-RX-API-DMAC10.html)
WO (1) WO2010011947A2 (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CN102065881B (zh) 2008-04-14 2014-03-12 埃尔奇诺瓦公司 稳定的淀粉样beta单体和寡聚体
US9045555B2 (en) * 2008-07-01 2015-06-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2542571B1 (en) * 2010-03-03 2016-05-25 The University of British Columbia Oligomer-specific amyloid beta epitope and antibodies
AU2013205000B2 (en) * 2010-03-03 2015-05-28 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
WO2011156003A2 (en) 2010-06-09 2011-12-15 New York University Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120089291A1 (en) * 2010-10-12 2012-04-12 Halder Bibhrajit Autonomous machine control system
WO2012072611A1 (de) * 2010-11-29 2012-06-07 Philipps-Universität Marburg SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER
ES2628596T3 (es) 2010-11-29 2017-08-03 Akershus Universitetssykehus Procedimientos y composiciones para monitorizar la actividad fagocítica
US9493515B2 (en) * 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
US20130164217A1 (en) * 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
DE102012021222B4 (de) * 2012-10-27 2015-02-05 Forschungszentrum Jülich GmbH Verfahren zur Herstellung einer nanoporösen Schicht auf einem Substrat
EP2746402A1 (en) * 2013-03-12 2014-06-25 Academisch Medisch Centrum Method of prognosis of Alzheimers disease and substrates for use therein
EP2787349A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
EP2787347A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CA2954031A1 (en) * 2014-07-07 2016-01-14 AbbVie Deutschland GmbH & Co. KG Immunogenic products based on mutein amyloid .beta. (.alpha..beta.) amino acid sequences and uses thereof
AU2015311836B2 (en) * 2014-09-05 2021-03-11 Presympto, Inc. Methods for detecting amyloid beta oligomers
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
WO2018005980A1 (en) * 2016-07-01 2018-01-04 The Scripps Research Institute Compositions and diagnostic methods related to transthyretin amyloid diseases
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN108148115A (zh) * 2018-01-30 2018-06-12 中国药科大学 一种环肽合成新方法及其在药物开发中的应用
WO2019246140A1 (en) * 2018-06-18 2019-12-26 Emory University Parallel enzyme digestion for protein biomarker detection
CN109851660A (zh) * 2019-03-20 2019-06-07 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽及其疫苗
CN109912687A (zh) * 2019-03-20 2019-06-21 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽药物
JP7357354B2 (ja) * 2020-02-04 2023-10-06 国立大学法人京都大学 アミロイドβ４２架橋アナログペプチド
KR102767892B1 (ko) * 2021-12-30 2025-02-14 고려대학교 산학협력단 신규한 단백질 변이체 및 이를 이용한 신경퇴행성 질환 치료용 조성물
US12037375B2 (en) * 2021-12-30 2024-07-16 Korea University Research And Business Foundation Protein variant and composition for treating neurodegenerative disease using the same
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease
WO2026136732A1 (en) 2024-12-18 2026-06-25 Cognition Therapeutics, Inc. Compositions and methods for the treatment of dementia with lewy bodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
US20020132758A1 (en) * 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
US20070213512A1 (en) * 2002-10-01 2007-09-13 Krafft Grant A Amyloid beta peptide analogs and assemblies thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
KR20080021585A (ko) * 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
JP2009518010A (ja) * 2005-11-30 2009-05-07 アボット・ラボラトリーズ ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用
ATE554085T1 (de) * 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase

Also Published As

Publication number Publication date
WO2010011947A3 (en) 2010-04-29
WO2010011947A2 (en) 2010-01-28
EP2303920A2 (en) 2011-04-06
EP2303920A4 (en) 2011-11-09
JP2011529084A (ja) 2011-12-01
MX2011000975A (es) 2011-05-25
CN102203124A (zh) 2011-09-28
US20110092445A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
US20110092445A1 (en) Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses
US20240075114A1 (en) IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
CN102459333B (zh) 抗-Tau pS422抗体用于治疗脑病的应用
CA2791538C (en) Oligomer-specific amyloid beta epitope and antibodies
KR20120042959A (ko) 아밀로이드 β(1-42) 올리고머, 이의 유도체, 이에 대한 항체, 이의 제조 방법 및 용도
JP2012521360A (ja) Ｋｖ１．３の選択的かつ強力なペプチド阻害剤
JP2000516572A (ja) プリオンタンパク質に結合し、イソ型ＰｒＰ▲上ｃ▼とＰｒＰ▲上ｓｃ▼を識別することが可能なシャペロン
WO2010010469A2 (en) Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
US11319348B2 (en) Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
JP4079775B2 (ja) β−アミロイドペプチドの可溶性環状類似体
Ball et al. Engineering the prion protein using chemical synthesis
AU2003288434B2 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
US20090099343A1 (en) Isolation of pathogenic prions
WO2004018511A2 (en) Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20250115638A1 (en) Peptide antigens for formylmethionine antibody production
WO2014014819A2 (en) Methods of treating glucose metabolism disorders
WO2013151627A1 (en) Methods of treating glucose metabolism disorders
BR112017000428B1 (pt) Produto imunogênico com base em sequências de aminoácidos muteína amiloide beta, composição compreendendo o produto e uso do mesmo para tratar ou prevenir amiloidose
WO2014014816A2 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150724